Arrowhead Research Corp.’s (ARWR) Hold Rating Reaffirmed at Jefferies Group
Arrowhead Research Corp. (NASDAQ:ARWR)‘s stock had its “hold” rating reaffirmed by equities researchers at Jefferies Group in a research note issued on Wednesday. They currently have a $2.00 target price on the stock, down from their prior target price of $5.00. Jefferies Group’s target price indicates a potential upside of 38.89% from the company’s current price.
Several other brokerages have also commented on ARWR. William Blair began coverage on shares of Arrowhead Research Corp. in a research note on Friday, August 19th. They set an “outperform” rating on the stock. Cantor Fitzgerald began coverage on shares of Arrowhead Research Corp. in a research note on Wednesday, August 17th. They set a “buy” rating and a $15.00 price target on the stock. Chardan Capital cut their price target on shares of Arrowhead Research Corp. from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 10th. Finally, Piper Jaffray Cos. cut their price target on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 10th. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. Arrowhead Research Corp. presently has an average rating of “Hold” and an average price target of $4.55.
Arrowhead Research Corp. (NASDAQ:ARWR) traded down 2.708% during midday trading on Wednesday, hitting $1.401. 3,077,713 shares of the stock traded hands. The company’s market cap is $85.11 million. Arrowhead Research Corp. has a one year low of $1.39 and a one year high of $8.22. The company’s 50 day moving average is $5.64 and its 200-day moving average is $6.10.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2016/11/30/jefferies-group-reaffirms-hold-rating-for-arrowhead-research-corp-arwr.html.
In other Arrowhead Research Corp. news, Director Douglas B. Given sold 12,000 shares of Arrowhead Research Corp. stock in a transaction on Friday, October 14th. The shares were sold at an average price of $6.72, for a total value of $80,640.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 3.90% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ARWR. Agran Libbie acquired a new position in Arrowhead Research Corp. during the third quarter worth approximately $135,000. BlackRock Group LTD increased its stake in shares of Arrowhead Research Corp. by 4.7% in the third quarter. BlackRock Group LTD now owns 20,563 shares of the company’s stock valued at $152,000 after buying an additional 929 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Arrowhead Research Corp. by 4,355.8% in the third quarter. Bank of Montreal Can now owns 22,502 shares of the company’s stock valued at $166,000 after buying an additional 21,997 shares during the last quarter. Quantitative Investment Management LLC purchased a new stake in shares of Arrowhead Research Corp. during the second quarter valued at $132,000. Finally, BlackRock Advisors LLC increased its stake in shares of Arrowhead Research Corp. by 4.6% in the second quarter. BlackRock Advisors LLC now owns 27,943 shares of the company’s stock valued at $149,000 after buying an additional 1,232 shares during the last quarter. Institutional investors own 43.28% of the company’s stock.
About Arrowhead Research Corp.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Receive News & Stock Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related stocks with our FREE daily email newsletter.